Xiaoying Yin

Title: Innovations of Xiaoying Yin in Cancer Research

Introduction

Xiaoying Yin is a notable inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of cancer research, particularly through his innovative work on the c-Myc oncoprotein. His research focuses on pharmacologic inhibition of Myc function, which is crucial in understanding and potentially treating various human cancers.

Latest Patents

Xiaoying Yin holds a patent for "Pharmacologic inhibition of Myc function." This patent addresses the c-Myc oncoprotein, a helix-loop-helix-leucine zipper (HLH-ZIP) transcription factor that is often deregulated in human cancers. The research identified seven low molecular weight substances that inhibit the association between c-Myc and Max, another HLH-ZIP protein. These compounds not only prevented this interaction in vitro but also inhibited the growth of c-Myc-expressing fibroblasts. Notably, short-term exposure to these compounds significantly reduced the tumorigenicity of c-Myc overexpressing fibroblasts in vivo. This work suggests that yeast-based assays can effectively identify inhibitors of protein-protein interactions, which may function in mammalian cells.

Career Highlights

Xiaoying Yin is affiliated with the University of Pittsburgh, where he continues to advance his research in cancer biology. His innovative approach to studying protein interactions has opened new avenues for therapeutic development in oncology.

Collaborations

Xiaoying has collaborated with esteemed colleagues, including Edward V Prochownik and Christine Giap, who have contributed to his research endeavors.

Conclusion

Xiaoying Yin's work exemplifies the intersection of innovation and cancer research, highlighting the potential for new therapeutic strategies against cancer. His contributions are paving the way for future advancements in the field.